Breaking News Instant updates and real-time market news.

NVS

Novartis

$80.08

0.22 (0.28%)

07:49
05/19/17
05/19
07:49
05/19/17
07:49

Novartis receives positive CHMP opinion for expanded use of Zykadia

Novartis announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has recommended approval of expanding the use of Zykadia to include the first-line treatment of patients with advanced non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive. The CHMP recommendation will now be reviewed by the European Commission, which holds the authority to approve medicines for the European Union. The EC typically follows the CHMP recommendation and typically issues an approval decision within two months, the company noted.

  • 19

    May

  • 06

    Jun

  • 26

    Jun

NVS Novartis
$80.08

0.22 (0.28%)

04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$99.51

1.4 (1.43%)

07:22
10/23/17
10/23
07:22
10/23/17
07:22
Periodicals
JPMorgan, Mosaic Smart Data partner to boost fixed-income trading, Reuters says »

JPMorgan has teamed up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CLVS

Clovis

$77.50

0.73 (0.95%)

07:21
10/23/17
10/23
07:21
10/23/17
07:21
Initiation
Clovis initiated  »

Clovis initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BIIB

Biogen

$338.10

-4.32 (-1.26%)

, ESALY

Eisai

$53.38

-0.25 (-0.47%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Hot Stocks
Biogen, Eisai expand existing collaboration agreement »

Eisai Co., Ltd. (ESALY)…

BIIB

Biogen

$338.10

-4.32 (-1.26%)

ESALY

Eisai

$53.38

-0.25 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

NITE

Nightstar Therapeutics

$19.00

-0.1 (-0.52%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Initiation
Nightstar Therapeutics initiated  »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Earnings
Potlatch reports Q3 EPS ex-items 94c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Hot Stocks
Potlatch raises dividend to 40c per share from 37.5c per share »

Potlatch announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAIC

SAIC

$70.88

1.04 (1.49%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Upgrade
SAIC rating change  »

SAIC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GGB

Gerdau

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Gerdau initiated  »

Gerdau resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Vale initiated  »

Vale resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$43.13

-0.16 (-0.37%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Southern Copper initiated  »

Southern Copper resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBR

Fibria Celulose

$16.24

0.45 (2.85%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Fibria Celulose initiated  »

Fibria Celulose resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Hot Stocks
Mike Covey to continue to serve as chairman and CEO of combined Potlatch, Deltic »

The leadership team will…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

GOOG

Alphabet

$988.20

3.75 (0.38%)

, GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Periodicals
Google plans to share revenues with news publishers, FT reports »

Google is planning to…

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

BIIB

Biogen

$338.10

-4.32 (-1.26%)

07:16
10/23/17
10/23
07:16
10/23/17
07:16
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Potlatch, Deltic Timber to combine in all-stock transaction »

Potlatch Corporation…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

PSTI

Pluristem

$1.77

-0.035 (-1.94%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Pluristem receives European patent covering PLX-R18 »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
10/23/17
10/23
07:15
10/23/17
07:15
General news
FX Update: The dollar traded firmer »

FX Update: The dollar…

HAL

Halliburton

$43.33

-0.09 (-0.21%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
Halliburton CEO says 'North American business is hitting on all cylinders' »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GNTX

Gentex

$19.38

-1.28 (-6.20%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Recommendations
Gentex analyst commentary  »

Gentex added to Alpha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WGO

Winnebago

$47.75

1.9 (4.14%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Recommendations
Winnebago analyst commentary  »

Winnebago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$9.25

0.47 (5.35%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
RedHill Biopharma receives notice of allowance for new U.S. patent for RHB-104 »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHE

Benchmark Electronics

$30.50

-0.5 (-1.61%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Conference/Events
Benchmark Electronics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 08

    Nov

USAP

Universal Stainless & Alloy

$21.79

1.24 (6.03%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Hot Stocks
Universal Stainless & Alloy announces favorable amendment of credit agreement »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NBIX

Neurocrine

$59.03

0.07 (0.12%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Hot Stocks
Neurocrine's Ingrezza granted FDA orphan status as Tourette syndrome treatment »

Neurocrine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MITK

Mitek Systems

$9.60

0.1 (1.05%)

07:12
10/23/17
10/23
07:12
10/23/17
07:12
Hot Stocks
Mitek Systems enters partnership with Asignio »

Mitek announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.